Literature DB >> 3019515

Constitutional interstitial deletion of 11p11 and pericentric inversion of chromosome 9 in a patient with Wiedemann-Beckwith syndrome and hepatoblastoma.

O A Haas, A Zoubek, E R Grümayer, H Gadner.   

Abstract

A constitutional interstitial deletion on the short arm of chromosome #11 and an inversion of the heterochromatin of chromosome #9 were detected in a 1.5-year-old boy with Wiedemann-Beckwith syndrome (WBS) and hepatoblastoma. Of 37 malignant and nine benign neoplasms reported in approximately 250 cases with complete and incomplete forms of WBS, this is the fourth patient with hepatoblastoma. To date, 28 cases of WBS have been cytogenetically investigated with banding techniques. Constitutional anomalies have been found in only nine cases: Various anomalies resulting in a common triplication of the 11p15 region in six cases, reciprocal translocations t(11;22) and t(X;1) and an inversion of chromosome #2 in the three remaining cases. Triplication 11p15 was only present in one of four cases with a tumor. The breakpoints of the unique del(11)(p11.1p11.2) present in our case are proximal to those of del(11p13-11p14) and dup(11p15) observed thus far in both the aniridia-Wilms' tumor association and in WBS. Inversion of chromosome #9--one of the heterochromatin variants associated with elevated chromosomal instability, increased congenital abnormalities, and cancer proneness--may have been causally connected with a genetic imbalance resulting in the de novo deletion of 11p11. Therefore, we suggest that in these high-risk groups, C-banding studies should be performed together with high resolution chromosome analysis in order to also reveal the incidence and significance of C-band variants in individuals with such cancer prone syndromes.

Entities:  

Mesh:

Year:  1986        PMID: 3019515     DOI: 10.1016/0165-4608(86)90409-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome.

Authors:  D Viljoen; R Ramesar
Journal:  J Med Genet       Date:  1992-04       Impact factor: 6.318

Review 2.  Mendelian cytogenetics. Chromosome rearrangements associated with mendelian disorders.

Authors:  N Tommerup
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

3.  Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5.

Authors:  A Koufos; P Grundy; K Morgan; K A Aleck; T Hadro; B C Lampkin; A Kalbakji; W K Cavenee
Journal:  Am J Hum Genet       Date:  1989-05       Impact factor: 11.025

Review 4.  Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome.

Authors:  A Slavotinek; L Gaunt; D Donnai
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

5.  Sex dependent transmission of Beckwith-Wiedemann syndrome associated with a reciprocal translocation t(9;11)(p11.2;p15.5).

Authors:  N Tommerup; C A Brandt; S Pedersen; L Bolund; J Kamper
Journal:  J Med Genet       Date:  1993-11       Impact factor: 6.318

6.  Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome.

Authors:  M H Little; D B Thomson; N K Hayward; P J Smith
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

7.  Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma.

Authors:  M Montagna; C Menin; L Chieco-Bianchi; E D'Andrea
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials.

Authors:  Daniel C Aronson; Piotr Czauderna; Rudolf Maibach; Giorgio Perilongo; Bruce Morland
Journal:  J Indian Assoc Pediatr Surg       Date:  2014-10

9.  Clinical, molecular- and cytogenetic analysis of a case of severe radio-sensitivity.

Authors:  K M Greulich-Bode; F Zimmermann; W-U Müller; B Pakisch; M Molls; F Würschmidt
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.